Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

Abstract: One aspect is a feedthrough system including a) a feedthrough including i) an insulating body, ii) an electrically conductive pathway, wherein an end of the electrically conductive pathway is level with a surface of the insulating body, iii) an electrically conductive pad, wherein the electrically conductive pad is attached to the level end of the electrically conductive pathway, b) an electrical contact element including a metal, wherein the electrical contact element is attached to the level end of the electrically conductive pathway by a joint microstructure, or wherein, when the feedthrough includes an electrically conductive pad, the electrical contact element is attached to the electrically conductive pad by a joint microstructure. Furthermore, the present embodiment refers to a process for preparing the inventive feedthrough system, and to a device including the inventive feedthrough system.

Abstract: An ablation system includes a retractable sheath including a lumen; a first electrode in the lumen; a pre-bent telescopic tube extendable from the lumen and including a second electrode, wherein the first electrode and the second electrode are configured to deliver an electric field energy to target tissue in a patient.

Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

Abstract: The present invention provides novel blockers of the potassium channel Kv1.3, polynucleotides encoding them, and methods of making and using them.

Abstract: The disclosure relates, inter alia, to a vehicle headlight (10), for example for a motor vehicle (1), wherein the vehicle headlight (10) comprises an illumination matrix (534) with a plurality of independently controllable illumination pixels for generating a (for example time-variant) illumination pattern, wherein the vehicle headlight (10) comprises an objective for imaging the illumination pattern, and wherein the objective comprises at least one objective lens.

Abstract: The present invention relates to anti-LAG3 antibodies, to methods of producing these molecules and methods of using the same.

Abstract: Herein is reported a co-cultivation system for co-cultivating a pool of rabbit B-cells or single deposited rabbit B-cells wherein cells CD40L expressing CHO cells are used as feeder in the presence of TL-2 and TL-21.

Abstract: The invention provides anti-S-HBs antibodies and methods of using the same.

Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

Abstract: The present invention relates to anti-PD1 antibodies and methods of using the same.

Abstract: The present invention relates to anti-PD1 antibodies and methods of using the same.

Abstract: The disclosure provides for cleaning three-dimensional (3D) components printed in a powder bed from adhering powder particles. The 3D-printed components are cleaned with a negative pressure-induced volumetric flow. The 3D-printed components are first removed from the powder bed after their manufacture, then positioned on a feed device and moved together with the feed device into a pressure-tight sealable chamber. In the interior of the chamber negative pressure is subsequently built up and a fluid volumetric flow is applied to the 3D-printed component to be cleaned which results in the powder particles being detached from the 3D-printed component. The powder particles are removed from the sealed chamber in a pressure tight manner via at least one channel conduit which is subjected to negative pressure and are fed to a separation device. The chamber is subsequently released of pressure and then opened for removal of the cleaned 3D-printed component.

Abstract: The invention relates to bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3. The invention further relates to methods of producing these molecules and to methods of using the same.

Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.

Abstract: The present invention relates to a process for producing a workpiece made of glass ceramics, and to the workpiece obtainable by the process according to the invention. Further, the invention relates to the use of the workpiece obtained as a dental restoration, and to a process allowing the translucency of a workpiece to be controlled.

Abstract: The present invention relates to anti-brain target agents and therapeutic uses thereof.

Abstract: The present invention relates to novel ICOS antibodies and tumor-targeted agonistic ICOS antigen binding molecules comprising them, pharmaceutical compositions comprising these molecules, and methods of using the same.

Abstract: The invention relates to bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3. The invention further relates to methods of producing these molecules and to methods of using the same.

Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.